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Abstract
Background: The objective consensus methodology has recently been applied in consensus finding in several
studies on medical decision-making among clinical experts or guidelines. The main advantages of this method are
an automated analysis and comparison of treatment algorithms of the participating centers which can be
performed anonymously.
Methods: Based on the experience from completed consensus analyses, the main steps for the successful
implementation of the objective consensus methodology were identified and discussed among the main
investigators.
Results: The following steps for the successful collection and conversion of decision trees were identified and
defined in detail: problem definition, population selection, draft input collection, tree conversion, criteria adaptation,
problem re-evaluation, results distribution and refinement, tree finalisation, and analysis.
Conclusion: This manuscript provides information on the main steps for successful collection of decision trees and
summarizes important aspects at each point of the analysis.
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Background
Evidence-based medicine (EBM) is the conscientious,
explicit, and judicious use of current best evidence in
making decisions about the care of individual patients
[1]. While randomized controlled trials are considered
to be the highest level of evidence [2], they are not
available for a significant proportion of clinical decisions
[3, 4]. In the absence of evidence several compensatory
strategies are being applied [5]. Due to technological ad-
vances, barriers in communication within the medical
community have been massively reduced enabling swarm-
like behavior of medical communities. Swarm-based medi-
cine [6], as a form of collective intelligence, represents an
additional source of information in decision making [6, 7].
In order to obtain information on medical decision
making from a swarm, i.e. the medical community, med-
ical information from individual medical care providers
[8–10] or different guidelines [11] needs to be collected
in a homogenous format for subsequent comparison and
analysis.
Decision trees can be used to visualize complex treat-
ment strategies and to compare treatment algorithms of
different individual entities [12]. When these are con-
structed with the same rule-set and terminology, their
comparison becomes possible [13]. By analysing recom-
mendations from every party for every permutation of
decision criteria, the majority decision for each permuta-
tion can be established. The advantage of such an ap-
proach is that the risk of bias through moderation or bias
towards individual trees is eliminated, this has been
termed the objective consensus methodology [14]. This
approach has been involved in various settings in clinical
oncology [15–18].
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The aim of this manuscript is to describe the steps
that are required to collect, refine and analyse decision
trees to determine consensus and controversy among ex-
perts, guideline panels or healthcare institutions for the
purpose of identifying trends in medical decision making
within a specified clinical setting.
Methods
The coordinating physicians from five finalized and two
ongoing cancer clinical care projects investigating pat-
terns of algorithms (treatment recommendations) were
asked to summarize the steps that were required to es-
tablish an analysis of multiple decision trees using the
objective consensus methodology [14]. The five con-
cluded projects involved an analysis of patterns of care
of radiotherapy and androgen deprivation therapy for
prostate cancer in Switzerland [15], the multidisciplinary
management of recurrent glioblastoma in Switzerland
[17] and a review of systemic therapies for metastatic
clear-cell renal cell cancer among international experts
[16, 18]. One project is investigating recommendations
of international guidelines for urolithiasis.
The ongoing projects investigate published guidelines
on Pompe’s disease, a rare metabolic myopathy, and
patterns of chemotherapy for metastatic pancreatic can-
cer, respectively.
The coordinators (CMP, TH, CR, JvR, VZ, MG) of the
projects were asked to describe their projects in an indi-
vidual list of steps performed (and problems encoun-
tered) during their respective projects. The steps within
these unformatted lists were manually compared (by
PMP) and steps with similar descriptions merged. All co-
ordinators participated in an unstructured discussion on
finding a common nomenclature and description for these
steps. The coordinators provided complementary informa-
tion and no conflicting experiences or recommendations
were reported. This resulted in a descriptive procedure
aimed at guiding investigators through this process, while
pointing out caveats experienced by the authors during
the concluded projects.
Results
Based on iterative discussions nine steps that applied to
all seven projects were identified (Fig. 1). The following
text will describe procedures within the individual steps
as well as problems associated with them.
Problem definition
The research question is defined and needs to be suit-
able for a decision tree analysis.
Implementing an objective consensus methodology is
associated with a certain workload, which is only cost-
efficient for problems which are complex enough to justify
Fig. 1 Workflow for patterns of algorithms analyses based on decision trees
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the effort. For a simple yes-no question based on 1 or 2
binary criteria a simple table would be a more efficient ap-
proach, classical surveys and accompanying discussions
would be a more efficient solution where multiple simple
questions are not directly linked to each other [10]. The
other extreme would be represented by decisions that are
so complex that it is not realistic to expect a clinical ex-
pert or guideline to even explicitly describe every possible
scenario (such as a comparison of every treatment for
every cancer for every type of patient), such a complexity
may be prohibitive.
It can be expected that decisions, which mostly rely on
individual factors such as patient preference, and other
parameters which are difficult to objectify will not be
adequately represented by decision trees.
To keep the scientific question on medical decision-
making clearly understandable, it is favourable to focus
on a specific medical condition to allow a detailed ana-
lysis of treatment algorithms. The problem investigated
needs to be specific enough to be categorizable. It is
pragmatic to avoid being too complex or extensive to
keep the workload in answering the questions reasonable
for the participants. For instance, the survey on primary
external beam radiotherapy of prostate cancer [15] with
and without androgen deprivation did not include a
comparison with other treatment modalities such as sur-
gery, brachytherapy or high intensity focused ultrasound
(HIFU), to keep the scientific question focused and to
allow for a detailed analysis of treatment parameters
related to the main question.
Population selection
A representative and unbiased group of participants is
selected.
One of the challenging issues encountered during the
mentioned projects included the fact that often a precise
cut-off for the target population (the “swarm subset”)
was difficult to define. When international experts are
the target [16, 18], no unprejudiced cut-off for whom to
include or exclude is possible. This was also critically
pointed out by the reviewers during the submission
process of these respective manuscripts. In the case of
national or territorial projects this issue should not pose
a problem, as in the survey on prostate cancer radiother-
apy in Switzerland [15] where all centres in Switzerland
were asked to participate. If an analysis of different
guidelines is performed, population selection criteria and
different health care systems must be defined and have
to be addressed as well (i.e. age limits in UK). In an
ongoing project analysed guidelines on the surgical man-
agement of urolithiasis, all guidelines were selected
based on the member list of the international society of
urology (SIU).
Ideally, group selection is explicitly defined, objective
and reproducible; if this is not possible, it must be
clearly stated that any conclusions from the analysis are
biased by the selection of the representatives being ana-
lysed [16]. For instance, a study on treatment options for
recurrent glioblastoma defined the inclusion criteria for
the survey as a representative of a tumour board of a
neuro-oncology centre with a scientific affiliation with
the Swiss Group for clinical cancer research (SAKK) and
the presence of an integrated neuro-surgery, radiation
oncology and medical oncology unit [17]. A study on
prostate cancer radiotherapy in Switzerland included all
hospitals with an independent unit for external beam
radiotherapy. For each centre, a board-certified radiation
oncologist was contacted who had the competence to
represent the current practice of his institution [15].
In a complex multimodality setting, the representatives
of the different centers need to be able to apply various
modalities. In case of the recurrent glioblastoma project
in Switzerland, individuals from each center represented
their respective multidisciplinary tumour boards. The
individuals were required to discuss their institutional
treatment recommendation with other specialists (e.g. if
the information was provided by a radiation oncologist,
the recommendation was approved by the neuro-surgeon
and the medical oncologist). This is critical as otherwise a
bias based on individual strategy within a center or bias
based on one’s own specialisation is probable [19, 20].
Draft input
The first unformatted input from the participants is
collected.
Based on our experience, in most centers, medical
treatments are not always explicitly defined in institu-
tional standard operating procedures or other forms of
explicit guidelines. And even if standard operating pro-
cedures exist explicitly, they may not cover every pos-
sible eventuality. Additionally, it cannot be expected that
participants produce a complete and non-conflicting
valid decision tree at their first attempt without previous
experience within a similar project. For this reason, the
first round of collected input can be automatically
regarded as draft input. Furthermore, sufficient time and
effort needs to be reserved to explain the concept of the
objective consensus methodology to the participants.
It is advisable to collect the data anonymously and
without the knowledge of the input from other centers
to avoid any bias. The participants should be provided
with the question alone without any examples or sample
answers. This is important as any predefined answers
may be suggestive and may influence the provided
recommendation. For several treatment strategies, the
general state of the patient is relevant, this may be repre-
sented by criteria such as fitness, age, comorbidities or
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performance status. It is important not to predefine
these terms to be able to differentiate later whether e.g.
age is an independent factor to fitness or performance
status. Also, when inquiring what the treatment recom-
mendation would be for patients over 70 years of age,
the actually used cut-off value of 65 years in a specific
case could be supressed.
The provided example (Fig. 2) shows a very simple
and first rough decision tree for metastatic pancreatic
cancer (PC). Despite its many flaws (age and fitness not
clearly differentiated, it is not clear when “GEM” (gemci-
tabine) is really used instead of best supportive care and
two recommendations for fit without differentiation are
provided), this is a first important step for further
discussion.
When guidelines are the target for analysis, at least two
authors should extract the recommendations from the
guidelines independently, followed by an appraisal where
potential discrepancies are discussed and resolved.
Tree conversion
Input from participants is converted into decision trees.
The first input may be provided in any format. Partici-
pating individuals should be burdened as little as possible
with technical issues, as this may affect the return rate
negatively; a rough incomplete paragraph on their strategy
can be very helpful to start the interaction and to refine
the details in an iterative approach. First versions of deci-
sion strategies were collected in various text-based and
graph formats. The coordinators converted this informa-
tion to first decision trees and identified open issues which
were discussed with the participant (see Fig. 3). In the ma-
jority of cases the first input received was not complete
and in many cases the first input was logically inconsistent
(with internal contradictions or several options without
preference).
This process was repeated until all inconsistencies and
gaps were resolved in the submitted decision tree. These
inconsistencies included conflicting multiple recommen-
dations for same combination of parameters or combi-
nations of parameters for which a recommendation was
not explicitly stated. Even though it is not intuitive, it is
of utmost importance that during the process the coor-
dinators do not judge the content of the decision trees
as this might cause the participant to adapt the treat-
ment recommendation and represents thus a potential
source for bias. Also, the coordinators should never
assume what the respondents meant without explicitly
stating it. Within these projects we observed multiple
treatment recommendations that were clearly beyond
or even contradictory to well-established evidence in
our view.
Criteria adaptation
Criteria used in decision trees are standardized.
In some instances, similar criteria may be named
differently by the participants. It is therefore important
that the coordinators are experienced in the context of
the study to mediate a common criteria adaptation
among the participants where it seems appropriate with-
out introducing further bias. For example, in the project
on recurrent glioblastoma [17] some treatments were
not recommended to patients that were considered “old”
or had a “poor performance status” (see Table 1). After
clarification with the participants an adequate replace-
ment term - “fit” or “unfit” - was found. By using merged
criteria, a meaningful comparison of different recommen-
dations was facilitated. Otherwise “poor performance sta-
tus” and “old” would need to be treated as independent
factors. From our experience, including items like per-
formance status, age, fitness and comorbidity as separate
parameters may lead to unnecessary complexity without
adding any value to the results.
Fig. 2 A sample draft decision tree, containing several imperfections. Text below the figure: (PC pancreatic cancer, BSC best supportive care,
Gem gemcitabine)
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Potentially a new criterion may be discovered after the
initial collection. In the renal cell cancer projects, several
participants mentioned the need for fast treatment, each
phrasing this criterion differently. We created a criterion
termed “Zugzwang” [16, 21] (to be forced to any action)
which was confirmed to be representative of their previ-
ous criteria. All centers were provided the opportunity
to incorporate this criterion. This enabled a cross-
comparison despite initially very different wording.
In all involved projects, certain criteria were defined
by individual participants that would not improve the
overall analysis but would lead to an exponential rise in
complexity and manageability. An example for such a
criterion was pulmonary fibrosis, a rare medical condi-
tion but a specific contraindication to a specific drug.
For all finalized projects the coordinators defined an
arbitrary threshold of at least e.g. three centers or guide-
lines mentioning a criterion to be included in the ana-
lysis. This threshold should be defined by practicability.
If any criteria are excluded this needs to be well docu-
mented and specifically stated.
When a criterion applies to the overall setting, such as
the patients’ informed consent to a treatment, this elem-
ent should not be included in the tree analysis but
extracted and discussed in the methodology or discus-
sion of a manuscript.
Problem re-evaluation
The initial research question is re-evaluated in light of
collected decision trees.
After refinement of the decision trees and simplifica-
tion and unification of decision criteria, the current
result needs to be re-evaluated in respect to the initial
problem definition. The initial problem definition was
defined at a point where the decision criteria as well as
recommendations of the participants were not known.
In certain situations, a re-definition through specification
of the initial problem may solve potential discrepancies.
For example, some individuals may propose to include
local treatments as alternatives to systemic treatment,
which was not initially considered by the coordinators. If
this is beyond the scope of interest or results in unman-
ageable complexity, specifying the problem as systemic
treatment excluding local options may be a solution. An-
other example may be to re-define the problem by adding
“in an otherwise healthy patient” to the definition of the
clinical scenario when several, but rare, comorbidities are
excluded as criteria.
This step is equally important in consensus analysis of
guidelines. If, for example, several panels recommend mul-
tiple therapies for a specific situation and list them in a
hierarchical manner, this may lead to unmanageably com-
plex consensus decision trees. In such cases defining the
“main recommended treatment” or “any recommended
treatment” might bridge this gap.
Results distribution
All used decision criteria are shared and participants
are provided the option to incorporate these in their
decision trees.
Fig. 3 A sample of the first decision tree sent to the participating centre for validation and correction. Text below the figure: At the stage of
refining the decision trees, any format can be used (in this example we used a decision tree in an email, which was discussed over phone, printed out
and corrected with pencil). mCCRCC: metastatic clear cell renal cancer HI: hepatic insufficiency, SUN: sunitinib, PS: performance status, ZZ: Zugzwang,
PAZ: pazopanib, HD IL-2: high-dose interleukin 2)
Table 1 Example of different cut-off values for performance
status, as initially collected for the trial investigating multimodal
management of recurrent glioblastoma [17]
Center Performance status Cut-off value
A KPS </> 50
B KPS </> 60
C KPS </> 70
D KPS </> 90
E ECOG ≤1,>1
F no specific scale good/bad
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The aim of this step is to distribute all collected deci-
sion criteria – but not all recommendations - to each
participant as well as their own recommendations in
decision tree format for comparison. Despite due dili-
gence on behalf of the participating centers, attention to
unconsidered aspects may be drawn upon by the input
of the other participants. For example, when active
treatment was discussed, individual centers provided
information on when to specifically not perform active
cancer treatment and instead provide best supportive
care. If these new aspects are included, all participants
should have the opportunity of re-addressing these issues
(see refinement Fig. 1).
Tree finalisation
All decision trees are finalized at a specific date.
As patterns of algorithms studies can be performed in
areas where controversy is expected, this may also be an
area where strategies are constantly evolving, e.g. due to
publications of trial results or due to updates of guide-
lines. The date of tree finalisation should be recorded to
ensure correct versioning and context.
Analysis
The decision trees are analysed for consensus and
discrepancies.
The analysis of decision trees based on objective con-
sensus can identify areas of controversy as well as con-
sensus. In the provided example (Fig. 4) from the trial
investigating the dose of radiotherapy and the length of
androgen deprivation therapy no single combination of
dose and length reached a majority, in several instances
not even a single dominant combination was identified.
Besides recommendations the criteria implemented can
be compared (Fig. 5), also the portfolio of treatments be-
ing offered by the participants may vary considerably and
can be visualised (Fig. 6).
Apart from descriptive statistics (e.g. congruency rate in
percentage for any decision), a clear definition of “consen-
sus” is needed, such as the most common (mode) recom-
mendation or a recommendation supported by more than
50% of the participating centers.
Discussion
Evidence-based medicine is considered the gold standard
for medical decision-making, but there are frequent situ-
ations where data are limited [3]. Consequently, many
clinical decisions are based on consensus recommenda-
tions in the lack of high-level evidence [6, 22]. The
objective consensus methodology as a means for consen-
sus analysis, can automatically compare multiple treat-
ment algorithms in the form of decision trees [14, 22].
There are several advantages of defining and analysing
clinical decision trees in this manner.
First, the objective consensus methodology does not re-
quire a specific initial input format from the participating
centres. A comprehensive questionnaire could facilitate
the generation and individual decision trees; this is how-
ever impractical due to the exponential combination of
implemented parameters. Also pre-defining criteria and
their cut-off values might supress criteria used in practice.
The externalization of intrinsic knowledge and every-day
know-how into the form of decision trees may cause prob-
lems [23]. It may therefore be beneficial to ask only for a
short free-text version of treatment recommendations
Fig. 4 A mode decision tree summarising and quantifying the radiotherapy recommendations of 24 Swiss centers for localised prostate cancer
[15]. Text below the figure: The figure shows very low consensus for radiotherapy dose and duration of androgen deprivation therapy based on
PSA value, T stage and Gleason score in prostate cancer. PSA = Prostate-specific antigen level (μg/L). Gl = Gleason. ADT = Androgen deprivation therapy
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which can be then converted into a decision tree by
the investigators and sent back for approval to the in-
dividual participant [14]. This approach has the ad-
vantage that the participants may not be biased in
their treatment recommendations by previously circu-
lating examples of decision trees.
By this means, a wide range of answers to potential
parameter combinations can be covered.
Additionally, the analysis of treatment recommendation
can be performed anonymously which may prevent a dis-
proportionate influence of individuals on the process of
consensus finding.
Fig. 5 Profile of criteria being used in decision making for recurrent glioblastoma, adapted from Hundsberger et al. [17]. Text below the figure: Criteria
used by a anonymised centers in decision making displayed by green squares, others in red. MGMT = O6-methylguanin-DNA-methyltransferase
promotor methylation status
Fig. 6 Treatment profile, the figures indicates the various treatments being offered in the context of first line metastatic renal cell cancer, adapted
from Rothermundt et al. [21]. Text below the figure: Recommended treatment option from a specific center are displayed by green squares,
others in red. The participating centres were named with their permission. INFα = interferon alpha; BEV = bevacizumab; SUN = sunitinib;
PAZ = pazopanib; SOR = sorafenib; AXI = axitinib; EVE = everolimus; TEM = temserolimus; BSC = best supportive care
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The objective consensus method provides a tool for
consensus analysis where the effort per party remains
constant potentially allowing an increased number of
participants, which is in contrast to many traditional
consensus finding methods [22].
The nominal group technique, which is also referred
as expert panel, consists of a generation and collection
of ideas concerning a specific topic with consequent dis-
cussion and ranking which is predominantly performed
in a person-to-person meeting [22, 24]. Although it al-
lows a high level of interaction and discussion between
the participants, there are several drawbacks: the num-
ber of participants may be very limited for practicability
reasons and therefore more biased than a consensus
analysis in a larger collective. Additionally, the lack of
anonymity may promote the influence of specific indi-
viduals and deter participants to express non-conformal
opinions.
Another commonly applied methodology for consen-
sus finding is the Delphi technique which provides a
form of highly structured group interaction by comple-
tion of questionnaires in several rounds which is per-
formed anonymously [24]. First, several statements on
specific medical issues are provided by invited experts or
based on a literature review and summarized in a ques-
tionnaire. Consequently, the participants rank their agree-
ment with each statement (e.g. on a scale from 0 to 9). In
a second round, the participants receive a summary of the
collected rankings and can adapt their score in view of the
responses of the other participants. The step of re-ranking
can be performed several times until a high level of con-
sensus is achieved [25]. The Delphi process shares with
the objective consensus methodology the possibility for
anonymous consensus analysis with a high number of par-
ticipants. However, the objective consensus methodology
deliberately avoids the disclosure of the group’s result to
each participant as this may bias the original opinion and
particularly affect participants with outlier positions. Add-
itionally, the Delphi process can only evaluate the extent
of agreement to predefined and well circumscribed state-
ments, but it cannot adequately compare complex treat-
ment algorithms (specifically the interaction of decision
criteria). For instance, in a consensus analysis on recurrent
glioblastoma, the Delphi progress could evaluate the level
of agreement with a statement such as “re-irradiation is a
treatment option for recurrent glioblastoma”. In contrast,
the objective consensus methodology gives each partici-
pant the opportunity to use (or omit) individual factors
and their combinations when to consider re-irradiation
such as tumour size, location, previous therapy or per-
formance status [17].
In daily routine, decision-making in controversial cases
is often supported by clinical guidelines. However, inter-
pretations of the available evidence can diverge in specific
points leading to different guideline recommendations
depending on the expert panel releasing them. Using con-
sensus analysis, controversial areas can be detected where
further research is needed [24]. Finally, the comparison of
individual decision trees can equally present disagreement
and consensus and may therefore depict controversial
issues more comprehensively than traditional consensus
finding methods which may remain inconclusive [14].
There are several limitations to this method. When
compared to registry-based patterns of care trials, the
numbers of specific situations are not collected and
whether patients are treated as defined in algorithms also
remains unproven.
Furthermore, treatment conditions of daily routine,
which have not been addressed in clinical trials, can be
addressed and agreed upon using the objective consen-
sus method. Widespread clinical expertise from different
physicians can be condensed in practical recommenda-
tions even though evidence is not available.
As mentioned in the section on problem definition, it
is recommended to define a concise question when the
objective consensus methodology is used: with too many
parameters or situations, the method still works, but
visualization and use of the results becomes more diffi-
cult, if not prohibitive. Therefore, the methodology is
not feasible for very complex treatment decisions with
consideration of multiple factors.
It should also be pointed out, that this method enables
identification of consensus recommendations if this con-
sensus is present. Identification of consensus is not its val-
idation, as the majority opinion is not inherently correct.
Decision-tree based analyses provide a valuable means
to summarise and quantify consensus for a given medical
situation. The usage of criteria in decision making as well
as the frequency of established treatments should be con-
sidered when considering feasibility and acceptance of
clinical trials. Decision trees can serve to identify trends in
interactions between criteria and recommendations in the
clinical setting (e.g. via multiple correspondence analysis).
By associating treatment, recommendations with costs
and applying distributions to decision criteria health eco-
nomic analyses become possible, including modelling
impact of changes in parameter distribution (e.g. ageing
population).
Conclusion
In conclusion, the collection of decision trees and appli-
cation of the objective consensus methodology requires
several consecutive steps from problem definition over
data collection and conversion to the final analysis,
which should be carefully planned. Several published
projects using this methodology demonstrate its feasibil-
ity. It is able to identify areas of consensus and hetero-
geneity/uncertainty, which can in turn serve as clinical
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research questions. Additionally, due to its simplicity it
can also provide important information for health care
authorities and health insurances to address reimburse-
ment issues in areas where no evidence is available, such
as rare diseases or rare clinical conditions.
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